Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Orders Pfizer And Wyeth To Divest Certain Operations As Condition To Merger Approval

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's Ministry of Commerce has ordered Pfizer and Wyeth to divest themselves of certain business operations here in order to gain government approval for their $68-billion merger

You may also be interested in...



Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B, Widening Nestle’s Reach In Emerging Markets

Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.

Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B, Widening Nestle’s Reach In Emerging Markets

Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.

Hong Kong's New Competition Law Could Have Impact On Drug Firms Around The World

BEIJING - Hong Kong's Legislative Council has begun reviewing a new competition bill that, depending on the contours of the law that is ultimately approved, could have a significant impact on the healthcare sector and life science-based enterprises, according to two lawyers who have closely studied the bill

Related Content

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel